This website is intended for UK healthcare professionals only
Prescribing information can be found here
Why invokana? for T2DM
Invokana Efficacy Icon

Glycaemic Efficacy

Invokana eliminates more blood glucose every day than any other SGLT2i 1-5

This is not a head-to-head study; results from phase 1 studies of urinary glucose excretion in patients with T2DM. 1-5

Invokana gets more patients to target than any other SGLT2i as add-on to metformin

In patients tolerating Invokana 100 mg who have an eGFR ≥ 60 mL/min/1.73 m2 and need tighter glycaemic control, the dose can be increased to 300 mg. 1,3-5

This is not a head-to-head study; figures are taken from respective Summary of Product Characteristics. 1,3-5

58% of patients given Invokana 300 mg in addition to metformin achieve the 7% target 4

Invokana is more effective at reducing HbA1c and weight than some other oral T2DM treatments

Weight loss with Invokana is an additional benefit only and not a licensed indication.

Head-to head studies are not available for all drug combinations; network meta-analyses (NMA) allow indirect treatment comparisons to be made.

Methodology: In an independent NMA using a frequentist model, pairwise random-effects were performed to estimate study variance. The aim of this NMA, which reviewed 38 trials involving 23,997 patients, was to assess the comparative safety and efficacy of SGLT2is in treating hyperglycaemia in adults with T2DM. Data was not available for ertugliflozin at the time of analysis.

Cardiovascular Outcomes
References
  1. Reference 10
  2. Sahasrabudhe V, et al. J Clin Pharm. 2017;57(11):1432-1443
  3. Reference 11
  4. Reference 7
  5. Reference 12
  6. Zaccardi F, et al. Diabetes Obes Metab. 2016;18(8):738-94